Concentrate for preparing solution
for infusion 100 mg/16,7 ml and 30 mg/5 ml
Trade name: paclitaxel.
International nonproprietary name: paclitaxel.
Description: oily clear colorless or yellowish liquid
Composition: 1 ml contains:
Active ingredients: semisynthetic paclitaxel- 6 mg.
Excipients: citric acid anhydrous, ethanol anhydrous, macrogolglycerol ricinoleate.
ATC code: L01CD01.
Indications for use:
► Ovarian cancer (the 1st line therapy (in combination with cisplatin) in patients with advanced metastatic or residual tumor (more than 1 cm) after laparotomy and the 2nd line therapy in patients with advanced metastatic ovarian cancer after unsuccessfull standard therapy).
► Breast cancer (adjuvant therapy in patients with lymph nodes metastasis after standard combination therapy, the 1st line therapy in metastatic cancer and the disease aggravation after adjuvant therapy with anthracyclines, the 2nd line therapy with the disease aggravation after combination chemotherapy with anthracycline antitumor antibiotics).
► Non- small cell lung cancer (the 1st line therapy in combination with cisplatin or monotherapy in patients who haven’t been planned for surgery and/or radiation therapy with the chance to be cured).
► Kaposi’s sarcoma in AIDS patients: the 2nd line therapy.
► Squamous cell carcinoma of head and neck.
► Transitional cell carcinoma of the bladder.
